TCGX | RoundOS

All recorded activity

By stage

Series B3

Series A1

Series C+1

Biotech5

United States3

Denmark1

Switzerland1

5 in all activity

Aug 11

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

$152MSeries B

Role not disclosed

Jun 24

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Apr 14

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed

Feb 18

Develops novel therapies to reduce the burden of neurodegenerative diseases

$175MSeries A

Role not disclosed

Jan 12

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B

Role not disclosed